摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Adamantan-1-ylmethyl-1-methyl-5-phenyl-1H-pyrrole-3-carboxylic Acid Ethyl Ester | 269070-83-9

中文名称
——
中文别名
——
英文名称
2-Adamantan-1-ylmethyl-1-methyl-5-phenyl-1H-pyrrole-3-carboxylic Acid Ethyl Ester
英文别名
ethyl 2-(1-adamantylmethyl)-1-methyl-5-phenylpyrrole-3-carboxylate
2-Adamantan-1-ylmethyl-1-methyl-5-phenyl-1H-pyrrole-3-carboxylic Acid Ethyl Ester化学式
CAS
269070-83-9
化学式
C25H31NO2
mdl
——
分子量
377.527
InChiKey
AQVJEYLDVSZZKJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.3
  • 重原子数:
    28
  • 可旋转键数:
    6
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    31.2
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-Adamantan-1-ylmethyl-1-methyl-5-phenyl-1H-pyrrole-3-carboxylic Acid Ethyl Ester盐酸sodium hydroxide 作用下, 以 1,4-二氧六环乙醇正己烷乙酸乙酯 为溶剂, 以51%的产率得到2-Adamantan-1-ylmethyl-1-methyl-5-phenyl-1H-pyrrole-3-carboxylic Acid
    参考文献:
    名称:
    Gastrin and cholecystokinin receptor ligands
    摘要:
    化合物的结构式(I)及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y独立地为═N—,—N(R5)—═CH—,—S—或—O—。n为1至4;R1为H或C1至C15烃基;R2从H,Me,Et,Pr和OH中选择;R3从H,Me,Et和Pr中选择;或(当n大于1时)每个R3独立地从H,Me,Et和Pr中选择,或相邻碳原子上的两个R3基团连接形成C3至C6碳环,或R2和R3在同一碳原子上共同表示一个═O基团;R4为C1至C15烃基;Z为—(NR7)a—CO—(NR8)b—(其中a为0或1,b为0或1,—CO—NR7—CH2—CO—NR8—,—CO—O—,—CH2—CH2—,—CH═CH—,—CH2—NR8—或键;Q为—R9V,或(II),(其中R9为—CH2—;—CH2—CH2—;或(III),R9和R8,与R8连接的氮原子一起形成被V取代的哌啶或吡咯烷环;V为—CO—NH—SO2—Ph,—SO2—NH—CO—Ph,—CH2OH,或具有式—R10U的基团,(其中U为—COOH,四唑基,—CONHOH—或—SO3H;R10为键;C1至C6烃基亚烷,—O—(C1至C3亚烷基)—;—SO2NR11—CHR12—;—CO—NR11—CHR12—,或—NH—(CO)c—CH2—,其中c为0或1)。
    公开号:
    US06479531B1
  • 作为产物:
    描述:
    2-adamantan-1-ylmethyl-5-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester碘甲烷N,N-二甲基甲酰胺 为溶剂, 以82%的产率得到2-Adamantan-1-ylmethyl-1-methyl-5-phenyl-1H-pyrrole-3-carboxylic Acid Ethyl Ester
    参考文献:
    名称:
    Gastrin and cholecystokinin receptor ligands
    摘要:
    化合物的结构式(I)及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y独立地为═N—,—N(R5)—═CH—,—S—或—O—。n为1至4;R1为H或C1至C15烃基;R2从H,Me,Et,Pr和OH中选择;R3从H,Me,Et和Pr中选择;或(当n大于1时)每个R3独立地从H,Me,Et和Pr中选择,或相邻碳原子上的两个R3基团连接形成C3至C6碳环,或R2和R3在同一碳原子上共同表示一个═O基团;R4为C1至C15烃基;Z为—(NR7)a—CO—(NR8)b—(其中a为0或1,b为0或1,—CO—NR7—CH2—CO—NR8—,—CO—O—,—CH2—CH2—,—CH═CH—,—CH2—NR8—或键;Q为—R9V,或(II),(其中R9为—CH2—;—CH2—CH2—;或(III),R9和R8,与R8连接的氮原子一起形成被V取代的哌啶或吡咯烷环;V为—CO—NH—SO2—Ph,—SO2—NH—CO—Ph,—CH2OH,或具有式—R10U的基团,(其中U为—COOH,四唑基,—CONHOH—或—SO3H;R10为键;C1至C6烃基亚烷,—O—(C1至C3亚烷基)—;—SO2NR11—CHR12—;—CO—NR11—CHR12—,或—NH—(CO)c—CH2—,其中c为0或1)。
    公开号:
    US06479531B1
点击查看最新优质反应信息

文献信息

  • [EN] GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RECEPTEURS DE LA GASTRINE ET DE LA CHOLECYSTOKININE
    申请人:BLACK JAMES FOUNDATION
    公开号:WO2000027823A1
    公开(公告)日:2000-05-18
    Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently =N-, -N(R5)- =CH-, -S- or -O-. n is from 1 to 4; R1 is H or C¿1? to C15 hydrocarbyl R?2¿ is selected from H, Me, Et, Pr and OH, R¿3? is selected from H, Me, Et and Pr; or (when n is greater than 1) each R?3¿ is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C¿3? to C6 carbocylic ring, or R?2 and R3¿ on the same carbon atom together represent an =O group; R4 is C1 to C15 hydrocarbyl Z is -(NR7)a-CO-(NR8)b- (wherein a is 0 or 1, b is 0 or 1, -CO-NR7-CH2-CO-NR8-, -CO-O-, -CH¿2?-CH2-, -CH=CH-, -CH2-NR?8¿- or a bond; Q is -R9V, or (II), (wherein R9 is -CH¿2?-; -CH2-CH2-; or (III), R?9 and R8¿, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is -CO-NH-SO¿2?-Ph, -SO2-NH-CO-Ph, -CH2OH, or a group of the formula -R?10¿U, (wherein U is -COOH, tetrazolyl, -CONHOH- or -SO¿3?H; and R?10¿ is a bond; C¿1? to C6 hydrocarbylene, -O-(C1 to C3 alkylene)-; -SO2NR?11-CHR12¿-; -CO-NR?11-CHR12¿-, or -NH-(CO)¿c?-CH2-, c being 0 or 1).
    式(I)化合物及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y独立地为=N-,-N(R5)-,=CH-,-S-或-O-。n为1至4;R1为H或C1至C15的烃基;R2从H,Me,Et,Pr和OH中选择,R3从H,Me,Et和Pr中选择;或(当n大于1时)每个R3独立地从H,Me,Et和Pr中选择,或相邻碳原子上的两个R3基团连接形成C3至C6的环烷基,或R2和R3在同一碳原子上共同表示一个=O基团;R4为C1至C15的烃基,Z为-(NR7)a-CO-(NR8)b-(其中a为0或1,b为0或1,-CO-NR7-CH2-CO-NR8-,-CO-O-,-CH2-CH2-,-CH=CH-,-CH2-NR8-或键;Q为-R9V,或(II),(其中R9为-CH2-;-CH2-CH2-;或(III),R9和R8,连同R8所连接的氮原子,形成被V取代的哌嗪或吡咯烷环;V为-CO-NH-SO2-Ph,-SO2-NH-CO-Ph,-CH2OH,或式-R10U的基团(其中U为-COOH,四唑基,-CONHOH-或-SO3H;R10为键;C1至C6的烃亚基,-O-(C1至C3的烷基)-;-SO2NR11-CHR12-;-CO-NR11-CHR12-,或-NH-(CO)c-CH2-,其中c为0或1)。
  • GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS
    申请人:JAMES BLACK FOUNDATION LIMITED
    公开号:EP1178969A1
    公开(公告)日:2002-02-13
  • US6479531B1
    申请人:——
    公开号:US6479531B1
    公开(公告)日:2002-11-12
  • Gastrin and cholecystokinin receptor ligands
    申请人:James Black Foundation Limited
    公开号:US06479531B1
    公开(公告)日:2002-11-12
    Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R5)—═CH—, —S— or —O—. n is from 1 to 4; R1 is H or C1 to C15 hydrocarbyl R2 is selected from H, Me, Et, Pr and OH, R3 is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or R2 and R3 on the same carbon atom together represent an ═O group; R4 is C1 to C15 hydrocarbyl Z is —(NR7)a—CO—(NR8)b— (wherein a is 0 or 1, b is 0 or 1, —CO—NR7—CH2—CO—NR8—, —CO—O—, —CH2—CH2—, —CH═CH—, —CH2—NR8— or a bond; Q is —R9V, or (II), (wherein R9 is —CH2—; —CH2—CH2—; or (III), R9 and R8, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is —CO—NH—SO2—Ph, —SO2—NH—CO—Ph, —CH2OH, or a group of the formula —R10U, (wherein U is —COOH, tetrazolyl, —CONHOH— or —SO3H; and R10 is a bond; C1 to C6 hydrocarbylene, —O—(C1 to C3 alkylene)—; —SO2NR11—CHR12—; —CO—NR11—CHR12—, or —NH—(CO)c—CH2—, c being 0 or 1).
    化合物的结构式(I)及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y独立地为═N—,—N(R5)—═CH—,—S—或—O—。n为1至4;R1为H或C1至C15烃基;R2从H,Me,Et,Pr和OH中选择;R3从H,Me,Et和Pr中选择;或(当n大于1时)每个R3独立地从H,Me,Et和Pr中选择,或相邻碳原子上的两个R3基团连接形成C3至C6碳环,或R2和R3在同一碳原子上共同表示一个═O基团;R4为C1至C15烃基;Z为—(NR7)a—CO—(NR8)b—(其中a为0或1,b为0或1,—CO—NR7—CH2—CO—NR8—,—CO—O—,—CH2—CH2—,—CH═CH—,—CH2—NR8—或键;Q为—R9V,或(II),(其中R9为—CH2—;—CH2—CH2—;或(III),R9和R8,与R8连接的氮原子一起形成被V取代的哌啶或吡咯烷环;V为—CO—NH—SO2—Ph,—SO2—NH—CO—Ph,—CH2OH,或具有式—R10U的基团,(其中U为—COOH,四唑基,—CONHOH—或—SO3H;R10为键;C1至C6烃基亚烷,—O—(C1至C3亚烷基)—;—SO2NR11—CHR12—;—CO—NR11—CHR12—,或—NH—(CO)c—CH2—,其中c为0或1)。
查看更多